Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Q24240731)

Elizabeth Tanjong Ghogomu

6

0 references

7

0 references

George Wells

3

George A Wells

0 references

Robin Christensen

Robin Christensen

2

1 reference

ORCID Public Data File 2021

Maria E Suarez-Almazor

4

Maria E Suarez-Almazor

0 references

Jasvinder Singh

1

Cochrane Database of Systematic Reviews

Jasvinder A Singh

0 references

publication date

7 October 2009

0 references

published in

0 references

cites work

Infliximab for the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Rituximab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Abatacept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Anakinra for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Evidence that cytokines play a role in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Second-line drug therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

New cytokine targets in inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

T cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Random-effects model for meta-analysis of clinical trials: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Quality of life in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Number needed to treat (NNT): implication in rheumatology clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Generalized linear mixed models for meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Evaluation of networks of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Macrophages and their products in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Explaining heterogeneity in meta-analysis: a comparison of methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

The Mast Cell in Inflammatory Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Work disability in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007848.PUB2

10.1002/14651858.CD007848.PUB2

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

743137

743137

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference